Company Overview

Curis is a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer. The Company currently has three drug candidates in development:

  • Fimepinostat (formerly known as CUDC-907), an orally available, small molecule inhibitor of HDAC and PI3K enzymes being investigated in a Phase 2 clinical trial in patients with MYC-altered diffuse large B-cell lymphoma and in a Phase 1 trial in patients with MYC-altered solid tumors.

  • CA-170, an orally-available, small molecule antagonist of VISTA and PD-L1 immune checkpoints being investigated in a Phase 1 clinical trial in patients with advanced solid tumors or lymphomas.

  • CA-4948, an orally-available, small molecule inhibitor of the IRAK4 kinase being investigated in a Phase 1 clinical trial in patients with non-Hodgkin's lymphoma.

Curis is engaged in a collaboration with Aurigene for discovery and development of drug candidates in the area of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule dual antagonists of PD-1 and VISTA, including VISTA/PD-L1 antagonist CA-170, and oral small molecule dual antagonists of PD-1 and TIM3, including TIM3/PD-L1 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948.

The Company's collaborators, F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, are commercializing Erivedge® (vismodegib) for the treatment of patients with advanced basal cell carcinoma, or BCC.